Benito-González T, et al. - In patients with implantable cardiac devices, researchers assessed ventricular arrhythmic (VA) burden prior to as well as following percutaneous mitral valve repair (PMVR). In this prospective registry, a total of 34 consecutive patients (age 69.0 ± 12.2 years, 77% male) were recruited from two centers. Participants had significant functional mitral regurgitation and had MitraClip implantation between June 2014 and July 2018. The total number of events during device follow-up before and post-PMVR defined VA burden. In this cohort, an attenuation in overall arrhythmic burden and ICD therapies was reported in relation to device success post-PMVR. A significant reduction in the VA burden, with a significant decrease in the occurrence of any VA and any ICD therapies, resulted from effective repair.